DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
HIMS logo

Hims & Hers Health, Inc. Stock Price

NYSE:HIMS Community·US$6.5b Market Cap
  • 9 Narratives written by author
  • 11 Comments on narratives written by author
  • 1120 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

HIMS Share Price Performance

US$27.89
-28.31 (-50.37%)
​
US$171.19
Fair Value
US$27.89
-28.31 (-50.37%)
83.7% undervalued intrinsic discount
US$171.19
Fair Value
Price US$27.89
Deep_Insights US$171.19
AnalystConsensusTarget US$31.23
BlackGoat US$86.09
Wed, 2 Sep 26
Fair ValueUS$171.19
Share Pricen/a

HIMS Community Narratives

DE
Deep_Insights
Deep_Insights's
Fair Value
·
Fair Value US$171.19 83.7% undervalued intrinsic discount

Hims & Hers Health Multidimensional Revenue Expansion

13users have liked this narrative
0users have commented on this narrative
76users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$31.23 10.7% undervalued intrinsic discount

Telehealth And Hormonal Health Will Transform Global Markets

12users have liked this narrative
0users have commented on this narrative
271users have followed this narrative
BL
BlackGoat
BlackGoat's
Fair Value
·
Fair Value US$86.09 67.6% undervalued intrinsic discount

Hims: The Platform Powering Personalised Healthcare

29users have liked this narrative
9users have commented on this narrative
145users have followed this narrative
HIMS logo
Hims & Hers Health
83.7% undervalued intrinsic discount

Hims & Hers Health Multidimensional Revenue Expansion

View narrative
DE
Deep_Insights
Deep_Insights
Updated 2 Sep
Read Narrative
HIMS logo
Hims & Hers Health
59.0% undervalued intrinsic discount

A Digital Healthcare Company Leader

View narrative
JO
jorgevalverde2366
Published 30 Jul
Read Narrative
HIMS logo
Hims & Hers Health
44.3% undervalued intrinsic discount

Long on HIMS

View narrative
AD
AdrianAnton
Published 20 Feb
Read Narrative
HIMS logo
Hims & Hers Health
4.5% undervalued intrinsic discount

Hims & Hers Health - Valuation

View narrative
AN
andre_santos
andre_santos
Updated 7 Mar
Read Narrative
HIMS logo
Hims & Hers Health
62.6% overvalued intrinsic discount

Hims & Hers are taking grip on Telemedicine

View narrative
WA
WallStreetWontons
Published 30 Apr 2024
Read Narrative
HIMS logo
Hims & Hers Health
67.6% undervalued intrinsic discount

Hims: The Platform Powering Personalised Healthcare

View narrative
BL
BlackGoat
Recommended Voice
BlackGoat
Updated 3 Jul 2025
Read Narrative
HIMS logo
Hims & Hers Health
10.7% undervalued intrinsic discount

Telehealth And Hormonal Health Will Transform Global Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 26 Aug
Read Narrative
HIMS logo
Hims & Hers Health
33.5% undervalued intrinsic discount

Telemedicine And AI Integration Will Redefine Digital Healthcare

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 9 Sep
Read Narrative
HIMS logo
Hims & Hers Health
21.3% overvalued intrinsic discount

Mounting Regulatory Costs And Intensifying Telehealth Competition Will Undermine Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 12 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

DE
Deep_Insights
HIMS logo

Geographical expansion has come visible

Fair Value: US$171.19 83.7% undervalued intrinsic discount
76 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
JO
HIMS logo

A Digital Healthcare Company Leader

Fair Value: US$68 59.0% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
andre_santos
HIMS logo

FY2025

Fair Value: US$29.21 4.5% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential and good value.

2 Risks
2 Rewards
View Full Analysis

Hims & Hers Health, Inc. Key Details

US$2.6b

Revenue

US$785.6m

Cost of Revenue

US$1.8b

Gross Profit

US$1.9b

Other Expenses

-US$142.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.61
69.53%
-5.51%
421.3%
View Full Analysis

About HIMS

Founded
2017
Employees
2442
CEO
Andrew Dudum
WebsiteView website
www.hims.com

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Recent HIMS News & Updates

Seeking Alpha • Sep 14

Hims & Hers: Pivot To Branded Distribution Is Eating The Margins Alive

Summary Hims & Hers has shifted to a branded pharmaceutical distribution model, compressing gross margins from 76% to 64% in one year. Despite 38% revenue growth in Q2, adjusted EBITDA declined 27% YoY, and free cash flow turned negative $68M, signaling deteriorating operating leverage. HIMS trades at a 24x forward EV/EBITDA premium, unsupported by negative incremental margins and a tangible book value of negative $1.2B. I rate HIMS a Hold; stabilization of gross margins above 62% and positive free cash flow in Q3 could justify a Buy. Read the full article on Seeking Alpha
User avatar
Narrative Update • Sep 09

HIMS: Novo Partnership And GLP 1 Expansion Will Drive Future Profitability

Hims & Hers Health's updated analyst price target has moved modestly higher from $40.00 to about $41.93, as analysts factor in refined revenue models across GLP-1 and newer categories, alongside expectations for stronger profitability and a lower future P/E multiple. Analyst Commentary Recent Street research on Hims & Hers Health points to a divided but generally constructive view.

Recent updates

No updates

Hims & Hers Health, Inc. Competitors

EW logo

Edwards Lifesciences

Symbol: NYSE:EW
Market cap: US$51.5b
BDX logo

Becton Dickinson

Symbol: NYSE:BDX
Market cap: US$49.5b
HUM logo

Humana

Symbol: NYSE:HUM
Market cap: US$46.2b
MDLN logo

Medline

Symbol: NasdaqGS:MDLN
Market cap: US$43.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide